Clinical Trials Logo

Clinical Trial Summary

This LIGHTSITE II study is a double-masked, sham-controlled, parallel design, prospective multi-site study for the use of PBM as a treatment for visual impairment in subjects with dry AMD.


Clinical Trial Description

This study is a double-masked, sham-controlled, parallel design, prospective multi-site study for the use of PBM as a treatment for visual impairment in subjects with dry AMD. The target enrollment is 96 subjects in up to 10 centers in Europe, randomized at a 1:2 ratio into 2 groups: Sham Treatment (S-1) and PBM Treatment (T-2). Once 96 subjects have been enrolled in the study, if there are less than 144 eyes that qualify for the study, additional subjects will be enrolled until 144 eyes have been included in the study. S-1 will receive 3 sham treatments per week over 3 to 5 weeks starting at Baseline and starting again at Months 4 and 8. T-2 will receive 3 PBM treatments per week over 3 to 5 weeks starting at Baseline and starting again at Months 4 and 8. Each treatment series will total 9 treatments. Neither the subject nor the study staff will know which treatment the subject has been assigned. Subjects will receive standard visual outcome measurements including Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA, CSV-1000E contrast sensitivity (CS) and the Radner Reading Test prior to and following each treatment series as well as eye exams, fundus photographs, Heidelberg OCT and FAF imaging and optional Optos Ultra Wide Field (UWF) imaging of the retina at selected time intervals. Subjects will also complete the Visual Function Questionnaire 25 (VFQ-25) at selected time intervals. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03878420
Study type Interventional
Source LumiThera, Inc.
Contact
Status Completed
Phase N/A
Start date February 14, 2019
Completion date January 22, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT03046407 - Treatment of Dry Age Related Macular Degeneration Disease With Retinal Pigment Epithelium Derived From Human Embryonic Stem Cells Phase 1/Phase 2
Active, not recruiting NCT04566445 - HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005 Phase 2
Recruiting NCT04339764 - Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration Phase 1/Phase 2
Active, not recruiting NCT05536752 - QA102 Phase II Study in Subjects With Dry AMD Phase 2
Active, not recruiting NCT04065490 - Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE III) N/A
Recruiting NCT06229665 - Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITEIIIB) Phase 2/Phase 3
Completed NCT01002950 - Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy Phase 2
Active, not recruiting NCT03333954 - Feasibility Study of Compensation for Blindness With the PRIMA System in Patients With Dry Age Related Macular Degeneration N/A
Completed NCT05667688 - Pharmacokinetics and Pharmacodynamics Study of LBS-008 in Healthy Volunteers Aged 50-85 Phase 1
Completed NCT01379560 - A Study to Evaluate the Ocular Blood Flow Effects of Unoprostone Isopropyl in Adults With Dry Age-related Macular Degeneration Phase 2
Completed NCT03144999 - Treatment of Advanced Dry Age Related Macular Degeneration With AAVCAGsCD59 Phase 1
Withdrawn NCT04511936 - Microcurrent Stimulation for Dry Age-related Macular Degeneration N/A
Withdrawn NCT04358471 - Intravitreal AAVCAGsCD59 for Advanced Dry Age-related Macular Degeneration (AMD) With Geographic Atrophy (GA) Phase 2
Terminated NCT04643886 - A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Dry Age-related Macular Degeneration Phase 2
Not yet recruiting NCT05418231 - Observation of the Natural Course of Age-related Macular Degeneration
Recruiting NCT00926861 - Posterior Macular Adhesion: A Potential Risk Factor for Non-exudative Age Related Macular Degeneration (AMD) to Develop Exudative AMD N/A
Active, not recruiting NCT04437368 - EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005 Phase 2
Active, not recruiting NCT03894020 - GTSCOPE - To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD)
Not yet recruiting NCT04875234 - Vision Improvement for Legally Blind Dry AMD Patients
Recruiting NCT02755428 - Subretinal Transplantation of Retinal Pigment Epitheliums in Treatment of Age-related Macular Degeneration Diseases Phase 1/Phase 2